Extended Data Fig. 6: Validation of the elevated plasma soluble VCAM1 level in patients with Alzheimer’s disease.
From: The VCAM1–ApoE pathway directs microglial chemotaxis and alleviates Alzheimer’s disease pathology
a,b, Cross-cohort validation of the elevated plasma soluble VCAM1 (sVCAM1) level found in patients with Alzheimer’s disease (AD). a, Violin plots showing the levels of plasma sVCAM1 in the PWH cohort (obtained from Jiang et al., 2021) (normal controls [NCs]: n = 74; AD: n = 106; two-tailed Mann–Whitney test). b, Correlation between the plasma levels of sVCAM1 and neurofilament light polypeptide (NfL) (linear regression). c-e, Cerebrospinal fluid (CSF) sVCAM1 level is not correlated with sex or APOE4 genotypes in patients with AD. c, Violin plot comparing sVCAM1 levels in CSF and plasma (CSF: n = 35; Plasma: n = 32; two-tailed Mann–Whitney test). d,e, Bar plots showing the effects of APOE4 gene dosage (e) (0: n = 3; 1: n = 14; 2: n = 9; Kruskal–Wallis test with Dunn’s multiple comparisons test) and sex (e) on sVCAM1 level in patients with AD (male: n = 18; female: n = 17; two-tailed Mann–Whitney test). Data are mean ± s.e.m.
